Risk factors
Zentalis Pharmaceuticals (ZNTL) risk factors
Item 1A of every Zentalis Pharmaceuticals, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors76 risks5 new7 dropped13 reworded
Zentalis added risks covering the 2022 Inflation Reduction Act, EU pharmaceutical legislation revisions, and the January 2025 workforce reduction. The company faces heightened regulatory and pricing scrutiny under new political administrations.
Filed Mar 26, 2026 - FY2024 10-K risk factors78 risks
Zentalis is a clinical-stage biopharmaceutical company dependent on its sole product candidate, azenosertib, which has no approved products and generates no revenue.
Filed Mar 26, 2025